- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04326686
Measuring Individual Responses to a Wholegrains and Nuts Intervention to Reduce Blood Pressure in Prehypertension (MI-DIET)
May 16, 2022 updated by: University of Aberdeen
Examining Factors Influencing Adherence to and Efficacy of a Wholegrains and Nuts Intervention to Reduce Blood Pressure in Prehypertension: a Series of N-of-1 Interventional Studies
The aim of the study is to investigate whether physiological, psychological and environmental factors, at an individual level, modify a) adherence, and b) blood pressure response, to a nuts and wholegrains intervention in participants at risk for developing high blood pressure.
For 24 weeks, participants will, on a daily basis, monitor their own blood pressure using a wireless blood pressure monitor and respond to short semi-personalised questionnaires using a wrist-worn device, which also measures activity levels.
Participants will receive an intervention of wholegrain foods and nuts to substitute into their diets for 8 weeks, between two 8-week observation periods.
The length of the study periods will enable repeated measurements to be taken, in order to assess what factors, on an individual level, are associated with fluctuations in the outcomes.
This will provide an insight into the types of factors that can help to explain individual fluctuations in adherence and physiological outcomes, such as blood pressure, that are common in nutrition studies.
In the future, this should help in tailoring the way the investigators deliver effective individualised interventions, and enable researchers to be better able to consider and control for factors that can affect adherence and response to dietary interventions.
Study Overview
Status
Completed
Conditions
Detailed Description
The study will be conducted as an interventional N-of-1 study with an A1-B-A2 design of 8 weeks per study period.
Prior to the study, participants will be screened and if eligible, will complete a number of baseline questionnaires to provide an overview of their typical eating and lifestyle-related behaviours, and general health.
A second visit prior to the start of the study will then be arranged, where participants will undergo a semi-structured interview.
Responses from the interview, in combination with their baseline questionnaire responses, will be used to identify factors specific to the participant that show some degree of variability.
These will form the basis of the semi-personalised questionnaires delivered via the wrist-worn PRO-Diary device for the duration of the study.
During the study, participants will visit the institute in a fasted state every 4 weeks (7 visits total), in order to provide a blood sample for assessment of cholesterol levels and for assessment of biomarkers of wholegrains intake.
At the first visit, participants will receive the wireless blood pressure monitor and PRO-Diary wrist device programmed with twice-daily questionnaires at times convenient to the participant.
After 2 weeks and every 4 weeks thereafter, participants will be sent a link by email to complete a 24-hour dietary recall.
After 8 weeks, participants will begin the intervention phase and receive wholegrains equivalent to 3 portions a day and 1 portion of unsalted nuts per day for the following 8 weeks.
Participants will be able to choose from a variety of wholegrain products commonly available at supermarkets.
They will also receive dietary advice to follow a Dietary Approaches to Stop Hypertension (DASH) diet aimed at lowering blood pressure.
All other measures will continue as previously.
At week 16, the wholegrains and nuts will be withdrawn and participants will be followed up for a further 8 weeks.
At their final visit to the institute, they will complete the same validated questionnaires as at baseline.
Results from the study will be analysed using N-of-1 dynamic modelling to analyse trends over time and determine whether any personalised factors significantly affected adherence to intervention or blood pressure response.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Aberdeen City
-
Aberdeen, Aberdeen City, United Kingdom, AB25 2ZD
- The Rowett Institute, University of Aberdeen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Mildly elevated blood pressure levels: systolic blood pressure (SBP) >120 <=140mmHg and/or diastolic blood pressure (DBP) >80 <=90mmHg.
- Low habitual intake of wholegrains: <=7 portions/week
- Body Mass Index (BMI) between 18-35
- Possessing a smartphone capable of running the Qardio app in conjunction with the QardioArm wireless blood pressure monitor
Exclusion Criteria:
- SBP <120 or >140mmHg or DBP <80 or >90mmHg. Participants with SBP > 140 or DBP > 90 will be advised to visit their GP to have their blood pressure reassessed in a clinical setting.
- Diagnosed with diabetes
- Clinically diagnosed with hypertension or hypercholesterolemia
- Unstable or untreated thyroid disorder
- Taking blood pressure- or cholesterol-lowering medications (e.g. beta blockers or statins)
- Following a low carbohydrate/gluten free diet
- Coeliac disease/gluten insensitivity
- Any food allergies
- Being on a weight loss diet or having lost >5kg in the last 6 months
- Any history of an eating disorder
- >7 portions/week habitual wholegrains consumption
- Having taken part in a study where wholegrains were provided in the last 3 months
- Not possessing a smartphone to run the Qardio app.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: N-of-1 study
For 24 weeks, each participant will measure their blood pressure and respond to questionnaires daily, and visit the institute to provide a blood sample every 4 weeks.
The study is split into three 8-week phases, the first of which will start when each participant is enrolled.
For the first 8-week observation phase (A1) the participant is instructed to continue with their usual diet and exercise habits.
For the second 8-week intervention phase (B), the participant will be provided with wholegrains and nuts and recommended to substitute these in place of refined grains and other snacks, respectively.
They will also receive dietary advice for following the Dietary Approaches to Stop Hypertension (DASH) diet.
For the final 8 week follow-up period (A2), provision of wholegrains and nuts will cease but the participant will continue with measurements at the same frequency as previously.
|
30g mixed unsalted tree nuts (almonds, hazelnuts and almonds) per day; 3 portions of wholegrain foods per day (including wholegrain cereal products, wholegrain bread and wholegrain pasta); guidance for following the Dietary Approaches to Stop Hypertension (DASH) diet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence to wholegrains and nuts consumption
Time Frame: 8-week intervention period
|
Number of portions of wholegrains consumed and whether a portion of nuts were consumed, reported daily via the PRO-Diary wrist device.
|
8-week intervention period
|
Change in plasma alkylresorcinol levels reflecting wholegrains intake
Time Frame: Every 4 weeks from start of study up to 24 weeks
|
Concentration of alkylresorcinols as a measure of wholegrains intake in nmol/L
|
Every 4 weeks from start of study up to 24 weeks
|
Change in blood pressure
Time Frame: From start of study up to 24 weeks
|
Blood pressure (both systolic and diastolic) will be taken daily by participants via the QardioArm wireless blood pressure monitor.
3 measurements are taken automatically and averaged.
|
From start of study up to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between adherence and blood pressure change
Time Frame: 8-week intervention period
|
Correlation between adherence and blood pressure change will be examined using N-of-1 dynamic modelling.
Daily blood pressure measurements and PRO-Diary questionnaire responses will be provided during the whole study.
Questionnaire responses will be given on a Visual Analogue Scale from 0-100.
|
8-week intervention period
|
Total, LDL and HDL cholesterol levels
Time Frame: 4-week blood samples
|
Fasted blood samples will be taken to determine whether wholegrains and nuts consumption has an effect on blood cholesterol levels.
|
4-week blood samples
|
Amount of wholegrains and nuts consumed during follow-up reported using PRO-Diary questionnaires
Time Frame: 8-week follow-up phase
|
For the final 8 weeks of the study, provision of wholegrains and nuts will cease but participants will continue to be asked about their consumption of these products through daily PRO-Diary questionnaires.
This is to determine if habit formation has occurred and led to continuation of consumption of these products
|
8-week follow-up phase
|
Determination of personal factors which correlate with study outcomes using Ecological Momentary Assessment (EMA) through the PRO-Diary device
Time Frame: 24 weeks
|
Participants will respond to semi-personalised questionnaires daily using a Visual Analogue Scale from 0-100 using the PRO-Diary device.
The PRO-Diary will also track movement collected during 60-second epochs via accelerometry.
The influence of these factors on the primary and secondary outcomes above will be aggregated using N-of-1 dynamic modelling.
Due to the semi-personalised nature of the questionnaires, the exact predictors examined in each N-of-1 study will differ.
Analysis of each N-of-1 study will be conducted separately.
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Baukje de Roos, The Rowett Institute, University of Aberdeen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 30, 2020
Primary Completion (ACTUAL)
March 25, 2022
Study Completion (ACTUAL)
March 25, 2022
Study Registration Dates
First Submitted
March 20, 2020
First Submitted That Met QC Criteria
March 26, 2020
First Posted (ACTUAL)
March 30, 2020
Study Record Updates
Last Update Posted (ACTUAL)
May 17, 2022
Last Update Submitted That Met QC Criteria
May 16, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MI-DIET
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prehypertension
-
Rockefeller UniversityCompleted
-
LycoRed Ltd.Maccabi Healthcare Services, IsraelCompletedPrehypertensionIsrael
-
Zhiming ZhuCompletedPrehypertensionChina
-
Vanderbilt UniversityCompleted
-
University of California, San DiegoEnrolling by invitationHypertension | Prehypertension
-
Brown UniversityNational Institutes of Health (NIH); National Center for Complementary and...CompletedHypertension | PrehypertensionUnited States
-
University of Colorado, BoulderForest LaboratoriesCompleted
-
University of Texas at AustinDairy Management Inc.CompletedHypertension | PrehypertensionUnited States
-
KGK Science Inc.Marealis ASCompletedPrehypertensionCanada, United States, Czech Republic, Germany
Clinical Trials on Dietary intervention: nuts and wholegrains with dietary advice for a blood-pressure lowering diet
-
University of ConnecticutCompleted
-
Johns Hopkins Bloomberg School of Public HealthMedifast, Inc.Completed
-
Fred Hutchinson Cancer CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedControlled Feeding Trial | Healthy Eating Index | Red Meat | MeatUnited States
-
Slotervaart HospitalCompletedHyperglycemia Steroid-inducedNetherlands
-
University of TorontoThe CIHR Social Research Centre in HIV PreventionCompleted
-
Instituto Nacional de Ciencias Medicas y Nutricion...Emory University; Universidad Nacional Autonoma de MexicoRecruitingObstructive Sleep Apnea of AdultMexico
-
Central Hospital, Nancy, FranceRecruitingCardiovascular Diseases | Risk Factors | Nutrition | Cohort Studies | GenotypeFrance
-
Pontificia Universidad Catolica de ChileUnknown
-
National Cancer Institute (NCI)CompletedAcute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1United States, Canada, Australia, New Zealand, Puerto Rico